Pergolide in the treatment of Parkinson's disease

No abstract is available for this paper.

• Publication year

  1984

• Venue

  Neurology

• Publication date

  1984-07-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1212/WNL.45.3_Suppl_3.S13PMID 7715792
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.

  1997cited by this paper
• Free radicals and their scavengers in Parkinson's disease.

  1993cited by this paper
• Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease

  1993cited by this paper
• Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide)

  1992cited by this paper
• Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Final report.

  1992cited by this paper
• Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats.

  1992cited by this paper
• A nationwide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. The fourth interim report.

  1991cited by this paper
• Third interim report of the nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients.

  1990cited by this paper
• Agonist substitution in advanced Parkinson's disease

  1989cited by this paper
• Lisuride, a dopamine agonist in the treatment of early Parkinson's disease

  1989cited by this paper
• The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years.

  1989cited by this paper
• Treatment of Parkinson's disease with pergolide: a double-blind study.

  1988cited by this paper
• Pergolide: long-term use in Parkinson's disease.

  1988cited by this paper
• MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.

  1988cited by this paper
• Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy.

  1988cited by this paper
• Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease

  1987cited by this paper
• Double-blind controlled study of pergolide mesylate in the treatment of Parkinson's disease.

  1987cited by this paper
• Long-term efficacy of pergolide in patients with Parkinson's disease.

  1986cited by this paper
• Double‐blind assessment of potential pergolide‐induced cardiotoxicity

  1986cited by this paper
• Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine.

  1986cited by this paper
• Double‐blind trial of pergolide for Parkinson's disease

  1985cited by this paper
• Long‐term study of pergolide in Parkinson's disease

  1985cited by this paper
• Differential diagnosis between radiation and tumor plexopathy of the pelvis

  1985cited by this paper
• Low dosages of bromocriptine added to levodopa in Parkinson's disease

  1985cited by this paper
• Chronic agonist therapy for Parkinson's disease

  1985cited by this paper
• Pergolide mesylate

  1985cited by this paper
• Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study.

  1985cited by this paper
• Long‐term experience with pergolide therapy of advanced parkinsonism

  1985cited by this paper
• The use of pergolide and lisuride, two experimental dopamine agonists, in patients with advanced Parkinson disease.

  1985cited by this paper
• Uncertainty in identification of blood group A subtypes by agglutination test.

  1985cited by this paper
• Orgasmic epilepsy

  1984cited by this paper
• Should Dopamine Agonists be Given Early or Late in the Treatment of Parkinson’s Disease?

  1984cited by this paper
• One-year trial of pergolide as an adjunct to Sinemet in treatment of Parkinson's disease.

  1984cited by this paper
• Biochemical and behavioral evaluation of pergolide as a dopamine agonist in the rat brain.

  1984cited by this paper
• Long‐term treatment with pergolide

  1984cited by this paper
• Pergolide therapy for Parkinson's disease

  1984cited by this paper
• Advances in Neurology: Experimental Therapeutics of Movement Disorders.

  1984cited by this paper
• Comparison of pergolide and bromocriptine therapy in parkinsonism

  1983cited by this paper
• Pergolide in Parkinson's disease.

  1983cited by this paper
• An evaluation of ambulatory, cassette EEG monitoring

  1983cited by this paper
• Methods for evaluating treatment in Parkinson's disease.

  1983cited by this paper
• The effects of pergolide on the cardiovascular system of 40 patients with Parkinson's disease.

  1983cited by this paper
• Prognostic factors for the occurrence of posttraumatic epilepsy.

  1983cited by this paper
• Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy

  1983cited by this paper
• Pergolide treatment in parkinsonism.

  1983cited by this paper
• Pergolide mesylate and idiopathic Parkinson disease

  1982cited by this paper
• Pergolide mesylate: new therapy for Parkinson disease.

  1982cited by this paper
• Further studies with pergolide in Parkinson disease

  1982cited by this paper
• Pergolide in late‐stage Parkinson disease

  1982cited by this paper
• Lisuride versus bromocriptine treatment in Parkinson disease

  1982cited by this paper
• Stimulation of pre- and postsynaptic dopamine receptors by an ergoline and by partial ergoline.

  1981cited by this paper
• Lisuride in parkinsonism

  1981cited by this paper
• Treatment of advanced Parkinson disease with pergolide

  1981cited by this paper
• PLEUROPULMONARY CHANGES DURING LONG-TERM BROMOCRIPTINE TREATMENT FOR PARKINSON'S DISEASE

  1981cited by this paper
• Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease.

  1981cited by this paper
• Evidence to support early levodopa therapy in Parkinson disease

  1981cited by this paper
• Bromocriptine and domperidone in the treatment of Parkinson disease

  1981cited by this paper
• Cardiac effects of pergolide

  1981cited by this paper
• Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease.

  1981cited by this paper
• Pergolide and lisuride for levodopa-induced oscillations.

  1981cited by this paper
• beta-adrenergic catecholamine regulation of lymphocyte sensitivity: heterologous desensitization to prostaglandin E2 by isoproterenol.

  1980cited by this paper
• Interaction of pergolide with central dopaminergic receptors.

  1980cited by this paper
• Pergolide mesylate: a potent day-long inhibitor of prolactin in rhesus monkeys and patients with Parkinson's disease.

  1980cited by this paper
• Dystonic foot response of Parkinsonism.

  1980cited by this paper
• Arteriovenous malformations of the brain. I: Current concepts and treatment.

  1980cited by this paper
• Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.

  1979cited by this paper
• Pergolide and lisuride for Parkinson's disease.

  1979cited by this paper
• Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease.

  1979cited by this paper
• Pharmacologic effects in man of a potent, long-acting dopamine receptor agonist.

  1979cited by this paper
• EFFECTS OF SOME NEW DOPAMINE AGONISTS ON PROLACTIN SECRETION AND TURNING IN 6-HYDROXYDOPAMINE LESIONED RATS

  1979cited by this paper
• Receptor basis for dopaminergic supersensitivity in Parkinson's disease

  1978cited by this paper
• Differences in the dopaminergic effects of the ergot derivatives bromocriptine, lisuride and d-LSD as compared with apomorphine.

  1978cited by this paper
• Neurotransmitter receptor alterations in Parkinson's disease.

  1977cited by this paper
• Bromocriptine in Parkinsonism

  1974cited by this paper
• Parkinsonism

  1967cited by this paper

• EKGDR: An End-to-End Knowledge Graph-Based Method for Computational Drug Repurposing

  2024cites this paper
• Non‐lesional treatments for tremor in Parkinson's disease: A systematic review and meta‐analysis

  2023cites this paper
• Alkyne Insertion Enabled Vinyl to Acyl 1,5-Palladium Migration: Rapid Access to Substituted Dihydrobenzofurans and Indolines.

  2023cites this paper
• Drug Repositioning Based on the Enhanced Message Passing and Hypergraph Convolutional Networks

  2022cites this paper
• Parkinson's disease

  2021cites this paper
• Predictive Value of Parkinsonian Primates in Pharmacologic Studies: A Comparison between the Macaque, Marmoset, and Squirrel Monkey

  2018cites this paper
• Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l-Dopa.

  2017cites this paper
• Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of Parkinson's disease

  2013cites this paper
• Update in Parkinson’s Disease

  2012cites this paper
• Cost-Effectiveness Analysis of Dopamine Agonists in the Treatment of Parkinson’s Disease in Japan

  2012cites this paper
• 1 Update in Parkinson ’ s Disease

  2012cites this paper
• Economic and Health-Related Quality of Life Considerations of New Therapies in Parkinson’s Disease

  2012cites this paper
• Early (Uncomplicated) Parkinson's Disease

  2010cites this paper
• Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinson’s Disease

  2010influential citation
• Late (Complicated) Parkinson's Disease

  2010cites this paper
• Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease.

  2009cites this paper
• Drug-induced fibrotic valvular heart disease.

  2009cites this paper
• Role of dopamine receptor agonists in the treatment of early Parkinson's disease.

  2009cites this paper
• Clinica e terapia della malattia di Parkinson

  2009cites this paper
• Direct Localization of Subthalamic Nucleus Supplemented by Single-Track Electrophysiological Guidance in Deep Brain Stimulation Lead Implantation: Techniques and Clinical Results

  2008cites this paper
• Pharmacotherapy and Treatment of Parkinson's Disease

  2007cites this paper
• Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson’s disease

  2007cites this paper
• Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease

  2006cites this paper
• Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study

  2006cites this paper
• Pergolide-associated valvular heart disease

  2006cites this paper
• Medical management of advanced Parkinson's disease.

  2006cites this paper
• Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease

  2006cites this paper
• The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease

  2006cites this paper
• Modifications neurochimiques au sein des ganglions de la base et comportements moteurs associés lors d'une stimulation électrique du noyau subthalamique chez le rat hémiparkinsonien ou de la mise en place de la dénervation dopaminergique chez le singe

  2006cites this paper
• Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease.

  2006cites this paper
• Dopamine Agonist Pergolide Prevents Levodopa-Induced Quinoprotein Formation in Parkinsonian Striatum and Shows Quenching Effects on Dopamine-Semiquinone Generated in Vitro

  2005cites this paper
• High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.

  2005cites this paper
• Parkinson's disease: aetiology, diagnosis, and management.

  2005cites this paper
• Dopamine receptor agonists in the therapy of Parkinson’s disease

  2004cites this paper
• Dopamine Agonists

  2004cites this paper
• Treatment challenges in early stage Parkinson's disease.

  2004cites this paper
• Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease.

  2003cites this paper
• Neuroprotective Strategies in Parkinson’s Disease

  2003cites this paper
• Dopamine agonists and their role in Parkinson’s disease treatment

  2003cites this paper
• Piribedil and bromocriptine in Parkinson's disease: a single‐blind crossover study

  2003cites this paper
• Appropriate dosing of pergolide in monotherapy and adjunctive therapy in Parkinson's disease

  2003cites this paper
• Comparing dopamine agonists in Parkinson's disease

  2003cites this paper
• Parkinson’s disease: Is the initial treatment established?

  2003cites this paper
• Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).

  2003cites this paper
• Prevention and treatment of motor fluctuations.

  2003cites this paper
• Medikamentöse Behandlung der idiopathischen Parkinson-Krankheit

  2003cites this paper
• Pergolide in the treatment of patients with early and advanced Parkinson's disease.

  2002cites this paper
• Management of Parkinson's disease: An evidence‐based review

  2002cites this paper
• Managing the critical problems of advanced Parkinson’s disease

  2002cites this paper
• Levodopa-induced Drowsiness in Healthy Volunteers: Results of a Choice Reaction Time Test Combined with a Subjective Evaluation of Sedation

  2001cites this paper
• Parkinson's disease: medical and surgical treatment.

  2001cites this paper
• Parkinson's disease and D 1 dopamine receptors

  2001cites this paper
• Choosing dopamine agonists in Parkinson's disease.

  2001cites this paper
• Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model.

  2001cites this paper
• Parkinson's disease and D1 dopamine receptors.

  2001cites this paper
• Pleuropulmonary disease due to pergolide use for restless legs syndrome.

  2001cites this paper
• Antiparkinsonian activity and dyskinesia risk of ropinirole and L‐DOPA combination therapy in drug naive MPTP‐lesioned common marmosets (Callithrix jacchus)

  2001cites this paper
• DRUG THERAPY IN THE MANAGEMENT OF PARKINSON ’ S DISEASE

  2001cites this paper
• Dopamine agonists: their role in the treatment of Parkinson's disease

  2000cites this paper
• Pharmacological treatment of Parkinson's disease

  2000cites this paper
• Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.

  2000cites this paper
• Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two‐year follow‐up study of previously untreated patients

  2000cites this paper
• Pergolide for levodopa-induced complications in Parkinson's disease.

  2000cites this paper
• The early treatment of Parkinson's disease: levodopa, dopamine agonists or both.

  2000cites this paper
• Long-term treatment with dopamine agonists in idiopathic in Parkinson's disease

  2000cites this paper
• Tremor-Predominant Parkinson’s Disease

  2000cites this paper
• Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease.

  2000cites this paper
• Tremor-Predominant Parkinson's DiseaseTo Treatment

  2000cites this paper
• Levodopa in Parkinson’s Disease

  1999cites this paper
• Ropinirole and Pramipexole, the New Agonists

  1999cites this paper
• The initial treatment of Parkinson's disease should begin with levodopa

  1999cites this paper
• Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.

  1999cites this paper
• Pergolide for levodopa-induced complications in Parkinson's disease

  1999cites this paper
• Klinik — orale Medikation

  1999cites this paper
• Macrophage Fcgamma receptors expression is altered by treatment with dopaminergic drugs.

  1999cites this paper
• Novos agonistas dopaminérgicos

  1999cites this paper
• Dopamine agonists.

  1999cites this paper
• [New dopaminergic agonists].

  1999cites this paper
• Cluster headaches

  1999cites this paper
• Medical treatment of later-stage motor problems of Parkinson disease.

  1999cites this paper
• Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors.

  1999cites this paper
• Rationale for Use of Dopamine Agonists in Parkinson's Disease: Review of Ergot Derivatives

  1999cites this paper
• Motor fluctuations in Parkinson's disease: pathophysiology and treatment

  1999cites this paper
• Pergolide monotherapy in the treatment of early PD

  1999cites this paper
• CJN volume 25 issue S1 Cover and Back matter

  1998cites this paper
• Do dopamine agonists provide neuroprotection?

  1998cites this paper
• Therapie des Morbus Parkinson mit α-Dihydroergocryptin in der neurologischen Praxis

  1998cites this paper
• Pretreatment with quinpirole inhibits the central antihypertensive effects of rilmenidine and α-methyldopa in conscious rats

  1997cites this paper
• Neuropsychiatric Adverse Effects of Antiparkinsonian Drugs

  1997cites this paper
• New Pharmacotherapy for Parkinson's Disease

  1997cites this paper
• Pretreatment with quinpirole inhibits the central antihypertensive effects of rilmenidine and alpha-methyldopa in conscious rats.

  1997cites this paper
• Pergolide in the management of restless legs syndrome: an extended study.

  1997cites this paper
• Therapie des Morbus Parkinson Teil 1: Standardtherapie motorischer und nicht motorischer Symptome

  1997cites this paper
• Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease

  1997cites this paper
• A review of the efficacy of the dopamine agonists pergolide and bromocriptine in the treatment of Parkinson's disease

  1997cites this paper
• New strategies with dopaminergic drugs: modified formulations of levodopa and novel agonists.

  1997cites this paper
• Comparative Review of Dopamine Receptor Agonists in Parkinson’s Disease

  1996cites this paper
• High‐dose pergolide monotherapy in the treatment of severe levodopa‐induced dyskinesias

  1996cites this paper
• Treatment of early Parkinson's disease: are complicated strategies justified?

  1996cites this paper
• A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine

  1995cites this paper